Literature DB >> 33783469

Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility.

G Caleb Alexander1,2, Scott Emerson3, Aaron S Kesselheim4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33783469     DOI: 10.1001/jama.2021.3854

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  38 in total

1.  Frustrated peptide chains at the fibril tip control the kinetics of growth of amyloid-β fibrils.

Authors:  Yuechuan Xu; Kaitlin Knapp; Kyle N Le; Nicholas P Schafer; Mohammad S Safari; Aram Davtyan; Peter G Wolynes; Peter G Vekilov
Journal:  Proc Natl Acad Sci U S A       Date:  2021-09-21       Impact factor: 11.205

Review 2.  Can we learn lessons from the FDA's approval of aducanumab?

Authors:  Kathy Y Liu; Robert Howard
Journal:  Nat Rev Neurol       Date:  2021-09-17       Impact factor: 42.937

Review 3.  Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer's Disease: A comprehensive review.

Authors:  Hannah W Haddad; Garett W Malone; Nicholas J Comardelle; Arielle E Degueure; Salomon Poliwoda; Rachel J Kaye; Kevin S Murnane; Adam M Kaye; Alan D Kaye
Journal:  Health Psychol Res       Date:  2022-07-28

4.  Aducanumab, a Novel Anti-Amyloid Monoclonal Antibody, for the Treatment of Alzheimer's Disease: A Comprehensive Review.

Authors:  Hannah W Haddad; Garett W Malone; Nicholas J Comardelle; Arielle E Degueure; Adam M Kaye; Alan D Kaye
Journal:  Health Psychol Res       Date:  2022-01-30

5.  Practice Effects in Mild Cognitive Impairment Increase Reversion Rates and Delay Detection of New Impairments.

Authors:  Mark Sanderson-Cimino; Jeremy A Elman; Xin M Tu; Alden L Gross; Matthew S Panizzon; Daniel E Gustavson; Mark W Bondi; Emily C Edmonds; Joel S Eppig; Carol E Franz; Amy J Jak; Michael J Lyons; Kelsey R Thomas; McKenna E Williams; William S Kremen
Journal:  Front Aging Neurosci       Date:  2022-04-25       Impact factor: 5.702

6.  Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US.

Authors:  Eric L Ross; Marc S Weinberg; Steven E Arnold
Journal:  JAMA Neurol       Date:  2022-05-01       Impact factor: 29.907

7.  Aducanumab produced a clinically meaningful benefit in association with amyloid lowering.

Authors:  Jeffrey Cummings; Paul Aisen; Cynthia Lemere; Alireza Atri; Marwan Sabbagh; Stephen Salloway
Journal:  Alzheimers Res Ther       Date:  2021-05-10       Impact factor: 6.982

8.  Proteomic analysis of human hippocampal subfields provides new insights into the pathogenesis of Alzheimer's disease and the role of glial cells.

Authors:  Yanpan Gao; Jiaqi Liu; Jiayu Wang; Yifan Liu; Ling-Hui Zeng; Wei Ge; Chao Ma
Journal:  Brain Pathol       Date:  2022-01-11       Impact factor: 7.611

9.  Aducanumab for Alzheimer's disease?

Authors:  Sebastian Walsh; Richard Merrick; Richard Milne; Carol Brayne
Journal:  BMJ       Date:  2021-07-05

10.  Safety and Efficacy of Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials.

Authors:  Eleonora Lacorte; Antonio Ancidoni; Valerio Zaccaria; Giulia Remoli; Leonardo Tariciotti; Guido Bellomo; Francesco Sciancalepore; Massimo Corbo; Flavia L Lombardo; Ilaria Bacigalupo; Marco Canevelli; Paola Piscopo; Nicola Vanacore
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.